Quick Facts: Butamir Therapeutic Domains

• Relief from Dry Cough: Butamir is indicated for the symptomatic management of dry, non-productive cough.
• Cough from Various Origins: It is used to address dry cough associated with diverse underlying causes.
• Pre- and Post-operative Use: It may be used to help manage cough before and after surgical procedures.

---

Butamir is a medication primarily focused on the symptomatic relief of dry cough. It is specifically used for coughs that are non-productive, meaning they do not result in the expulsion of mucus or phlegm.

The therapeutic purpose of Butamir is to help decrease the frequency and intensity of persistent, dry coughing episodes. Its use is generally intended for the short-term management of irritating coughs that may be present due to various respiratory tract conditions. It is used in addressing dry cough of diverse origins, including coughs that may follow a recent viral infection.

Additionally, Butamir may be utilized in clinical settings for the management of cough in patients preparing for, or recovering from, surgical procedures such as bronchoscopy. It is a supportive measure for temporary cough concerns.

Regulatory References

1. FDA Verification Portal

Eligibility Map: Who can and cannot use Butamir — official regulatory information

The eligibility profile for Butamirate citrate is defined by official governmental regulations concerning specific patient populations, age groups, and concurrent health conditions.

---

Eligibility scope

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with known hypersensitivity to the drug or excipients; children under 3 years of age (for specific forms); individuals with rare hereditary fructose intolerance.
Populations for whom use is not recommended	Pregnant individuals during the first trimester; mothers who are breastfeeding.

---

Condition-specific eligibility rules

• Organ Function: Caution is advised for patients with renal or hepatic impairment because safety data for these populations is lacking in regulatory studies.
• Concomitant Treatment: Use must be avoided in patients concurrently receiving expectorants (mucus-clearing agents) to prevent complications from mucus stagnation.
• Pregnancy Status: Use is conditional and requires caution during the second and third trimesters, permitted only if absolutely necessary.

---

The regulatory profile establishes clear age cutoffs and absolute prohibitions based on hypersensitivity or excipient intolerance. It further advises caution for patients with hepatic or renal impairment where clinical data is insufficient, and mandates that use must be avoided when the patient is concurrently taking expectorants, ensuring adherence to strict eligibility criteria.

Interactions with other medicines and products

The interaction profile of Butamirate Citrate is characterized by specific regulatory restrictions, primarily concerning pharmacodynamic conflict and pharmacokinetic cautions documented in official prescribing information.

---

Documented Interaction Restrictions

Interacting Product Category	Regulatory Constraint	Interaction Outcome Classification
Expectorants (Mucus-Clearing Agents)	Co-administration is prohibited (must be avoided).	Pharmacodynamic Conflict (Risk of mucus accumulation)
Strong Enzyme Inhibitors	Co-administration should be avoided.	Pharmacokinetic Caution (Risk of increased Butamirate exposure)
Medicinal Products with a Narrow Therapeutic Index	Co-administration should be avoided.	Pharmacokinetic Caution (Possible risk of altering co-administered drug exposure)

---

The mandatory prohibition against combining butamirate with expectorants stems from the risk of mucus accumulation in the respiratory tract. This accumulation may lead to subsequent complications such as bronchospasm or respiratory tract infections, establishing a severe pharmacodynamic restriction. The caution regarding strong enzyme inhibitors addresses the possible increased plasma concentration of butamirate, a pharmacokinetic effect. No specific timing-based separation rules or interactions with food, alcohol, or herbal products are formally documented in the regulatory interaction sections.

Central Modulation of the Cough Reflex Center

This domain covers the primary biological target: the Cough Center in the medulla oblongata of the brainstem. The drug's mechanism involves inhibition of the central neural pathways, which elevates the neurological threshold required to initiate a cough. This action on the central system modulates the reflex via a non-opioid binding site, avoiding interaction with mu-opioid pathways.

Peripheral Airway Resistance Modulation

This domain addresses the drug's secondary mechanistic role: its action on the respiratory tract. Butamirate exerts a bronchodilatory effect by modulating the tone of the bronchial smooth muscle. This physiological consequence results in a reduction in airway resistance, which complements the central mechanism by resulting in a reduction of mechanical strain associated with bronchial tone.

How to Use Butamirate Citrate: Administration Guidelines

Butamirate citrate is administered exclusively via the oral route. Its administration must strictly adhere to the dosing schedules established for the specific pharmaceutical form and the patient’s age group.

Dosage and Frequency

The medicine is available as a syrup, oral drops, and sustained-release (SR) tablets. Dosing for adults using the syrup is typically 15 mL up to four times daily, with a defined maximum daily limit of 90 mg. Alternatively, adults may be instructed to use the SR tablets, typically taking 2 to 3 tablets per day at intervals designed to maintain concentration, often every 8 to 12 hours.

Population-Specific Use

Administration for pediatric patients is strictly tiered by age or weight, necessitating accurate measurement of the liquid forms. For instance, children aged 6 to 12 years are directed to take a lower volume, such as 10 mL three times daily, while adolescents over 12 years use the adult 15 mL three-times-daily regimen.

Procedural Instructions and Duration

Treatment is intended for short-term use, limited to the symptomatic period. If a scheduled dose is missed, a patient should not take a double dose to compensate; the regular schedule should be maintained with the next dose. The SR tablets are generally taken with or without food. The fundamental use pattern requires selecting the correct dosage form and adhering to the fixed daily frequency and maximum dose established in the prescribing information.

Research Evidence / Overview of Studies for Butamirate Citrate

This section provides a factual overview of the scientific evidence for butamirate citrate, summarizing the types of studies conducted and the patterns observed, without offering clinical advice or treatment recommendations.

---

Research Evidence for Symptomatic Relief of Dry, Non-Productive Cough

The primary research for butamirate citrate focused on studying conditions characterized by persistent, irritative, or non-productive cough. Studies exploring this focused use include short-term Randomized Controlled Trials (RCTs) and other comparative designs. Researchers were primarily interested in measuring patient-reported scores on cough severity and frequency over defined time intervals.

Studies monitored how patient-reported cough severity and the number of coughing episodes evolved in the observed populations. Some trials were designed to explore the relationship between the medicine and the cough reflex itself, where cough was induced in healthy volunteers. Some studies reported measurements where the measured reflex response was observed to lessen in some instances.

---

Comparison with Other Non-Narcotic and Narcotic Antitussives

Studies have been conducted to compare butamirate citrate against other cough suppressants, including both non-narcotic agents like dextromethorphan and opioid-based formulations like codeine. In comparative trials involving codeine-based products, research described patterns where the measurements for butamirate citrate were sometimes observed to differ from those of the comparator. However, when compared to dextromethorphan using certain objective measures, butamirate failed to show significant activity in that specific model.

---

Follow-up Duration and Long-Term Outcomes

Research exploring symptom changes with butamirate citrate has primarily focused on short-term outcomes. The typical follow-up durations in the pivotal efficacy trials were limited, often lasting only five days. As a result, long-term effects are not fully established, and there is limited information for long-term outcomes or sustained symptom relief.

---

Recognized Research Gaps and Uncertainties

The evidence landscape for butamirate citrate has been generally characterized by scientific reviewers as having a moderate level of certainty. These limitations include the older methodology of some supporting trials, mixed findings from objective cough reflex tests, and a general scarcity of evidence for sustained use or in specific patient cohorts, particularly those with kidney or liver impairment.

Key Studies & References

1. Butamirate citrate Summary of Product Characteristics (Example Regulatory Data)

Common questions about Butamir (FAQ)

---

Q: Is Butamir available without a prescription?

The regulatory classification of Butamirate citrate preparations varies depending on the specific country and the product strength. In certain regions, the medicine is officially classified as an Over-The-Counter (OTC) product, meaning it may be purchased without a prescription. The final classification depends on the specific country and product form.

---

Q: How quickly does Butamir start working?

Official pharmacokinetic data describes the timeline of the medicine’s absorption and action in the body. Following oral administration of the syrup form, the primary metabolite that contributes to the cough-suppressing action reaches its highest concentration in the bloodstream in approximately 1.5 hours. This measure provides an indication of the onset of the drug's activity after being taken.

---

Q: How long do the effects of Butamir last?

The duration of the effect is related to how long the active substances remain in the body. Official data indicates the apparent half-life of the main substance is about 6 hours. However, other active metabolites that suppress the cough have a longer half-life, which can be around 18 hours.

---

Q: Is Butamir safe for people with asthma?

Regulatory documents caution that the underlying cause of a cough should always be investigated before using any antitussive medication. The regulatory label strictly prohibits using Butamirate alongside expectorants (mucus-clearing agents). Suppressing a cough in this context may be associated with the risk of mucus stagnation, which can potentially lead to complications like bronchospasm or respiratory tract infections.

---

Q: Can Butamir be taken with anti-anxiety medicine?

Official product information does not list specific interactions with all anti-anxiety medicines. However, regulatory caution advises against the use of Butamirate alongside medicinal products that have a 'narrow therapeutic index.' This refers to drugs where a small change in dosage or blood level can be associated with toxicity, and co-administration may alter the exposure to these sensitive drugs.

---

Q: Does Butamir interact with common cold medications?

Yes, there is a key restriction noted in official regulatory labeling. The simultaneous use of Butamirate with expectorants—which are common components in many cold and flu medicines—is strictly contraindicated (prohibited). Regulatory warnings note that this combination may lead to mucus accumulation in the airways, increasing the risk of respiratory infections.

---

Q: Can I take Butamir if I have diabetes?

The regulatory label notes that Butamirate liquid preparations may contain sorbitol, which is a sugar substitute. Because of this component, the medicine is contraindicated for individuals who have rare hereditary problems of fructose intolerance. This specific contraindication should be reviewed against any personal health conditions.

---

Q: What should I do if I think Butamir is not working for me?

Official warnings advise against increasing the dose if the cough persists while taking the recommended amount. If the cough lasts longer than four to five days, or if new symptoms such as fever, shortness of breath, or chest pain develop, official guidance suggests seeking medical advice.

---

Q: Is Butamir used in other countries for different conditions?

The primary purpose is the symptomatic relief of dry, irritant coughs. However, official product information in some countries indicates additional approved uses. These may include cough suppression for specific medical procedures like bronchoscopy, or for coughs associated with certain conditions like pertussis (whooping cough).

---

Q: Does taking Butamir require any specific monitoring?

Routine clinical monitoring is not mandated for all patients using the drug. However, regulatory documents note that individuals with reduced liver or kidney function may be at a greater risk for adverse effects. Additionally, official overdose guidance focuses on the clinical monitoring and treatment of vital signs.

---

Q: What happens if I accidentally take more Butamir than intended?

Butamirate overdose may lead to symptoms such as drowsiness, dizziness, vomiting, nausea, diarrhea, and low blood pressure (hypotension). Official guidance for managing an overdose focuses on monitoring vital signs and providing symptomatic support.

---

Q: Do studies support the use of Butamir for nighttime cough?

Clinical research supporting the regulatory approval of Butamirate has examined its impact on patients’ daily lives. Studies reported findings that included improvements in the quality of sleep and fewer coughing episodes when compared to certain other antitussive combinations.

Storage and Disposal Requirements

Official regulatory labeling outlines specific conditions necessary to maintain the stability and integrity of Butamirate preparations.

Storage Conditions

Butamirate must be stored at a temperature not exceeding 30 C and must not be frozen, particularly for liquid forms like syrup. The medicine requires protection from environmental factors, including light and moisture. To maintain product integrity, the medicine must be kept in its original container and the container must remain tightly closed.

Child Safety and Disposal

It is a mandatory regulatory requirement to store Butamirate out of the reach and sight of children. For disposal of unused or expired product, the preferred method is a drug take-back program. If this is unavailable, the medicine should be disposed of in the household trash following government-approved guidelines, which strictly state do not flush the product down the toilet or pour it down a drain.